Detection Technology (DETEC) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales reached EUR 26.1 million, up 3.5% year-over-year, with record industrial and strong security sales offsetting weak medical sales.

• EBITA improved to EUR 3.3 million (12.7% margin), more than doubling from the prior year, driven by improved productivity and sales mix.

• H1 2024 net sales totaled EUR 48.8 million, up 1.7% year-over-year, with EBITA at EUR 5.6 million (11.4% margin).

• Security became the largest business unit, accounting for 44% of sales, followed by medical (36%) and industrial (20%).

• Early repayment of the Haobo Imaging acquisition loan was enabled by strong cash flow.

Financial highlights

• Q2 EBITA was EUR 3.3 million (12.7% margin); H1 EBITA was EUR 5.6 million (11.4% margin).

• Earnings per share for Q2 was EUR 0.15; H1 EPS was EUR 0.26.

• R&D spending was EUR 3.0 million in Q2 (11.7% of sales); H1 R&D was EUR 5.6 million (11.4% of sales).

• Cash flow from operations was EUR 3.9 million in Q2 and EUR 6.8 million in H1.

• Dividend of EUR 3.4 million paid in Q2.

Outlook and guidance

• Double-digit net sales growth is expected for Q3 and H2 2024, with all business units projected to grow.

• Full-year guidance: at least 10% annual growth, 15%+ EBITA margin, and 30–60% dividend payout.

• Medical segment expected to recover in H2 as China’s healthcare anti-corruption campaign eases.